Blog Posts - Genotype 1a



ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT...
by Hepatitis C Research and News on Apr 25, 2015

Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant

16 December 2013 Summary: Naturally occurring mutations in the hepatitis C virus (HCV) are common and many lead to reduced efficacy of antiviral treatments. Faldaprevir* has now been shown to be effective even in patients with the common HCV Q80K...
by Hepatitis C Research and News on Dec 16, 2013

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

10 September 2013 First Phase IIa study includes Presidio’s PPI-668 in genotype-1a infected patients1; collaboration offers the potential to explore additional HCV genotypes in future trials Boehringer Ingelheim’s Phase III interferon-free HCVer...
by Hepatitis C Research and News on Sep 10, 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Published on July 30, 2013 at 6:32 AM Interview conducted by April Cashin-Garbutt, BA Hons (Cantab) Please can you give a brief introduction to genotype-1b hepatitis C and how it differs from subtype 1a? Genotype 1 is, worldwide, the most prevalen...
by Hepatitis C Research and News on Jul 30, 2013


Trending Topics

Close